City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Vincent Chung, MD  
Search results:  7  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-7 Trials Jump to page:

COH Protocol Number: 16215 ClinicalTrials.gov Number: NCT02030067

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced Malignancies

COH Protocol Number: 15320

Principal Investigator: Vincent Chung, MD
Sponsor: Institutional

Title:  The Total Cancer Care Protocol: A Lifetime Partnership with Patients of the City of Hope

COH Protocol Number: 15002 ClinicalTrials.gov Number: NCT02432963

Principal Investigator: Vincent Chung, MD
Sponsor: Institutional

Title:  A Phase I Study of a p53MVA Vaccine in Combination with Pembrolizumab

COH Protocol Number: 14122 ClinicalTrials.gov Number: NCT02336087

Principal Investigator: Vincent Chung, MD
Sponsor: Institutional

Title:  A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients with Unresectable Pancreatic Cancer

COH Protocol Number: 13464 ClinicalTrials.gov Number: NCT01959139

Principal Investigator: Vincent Chung, MD
Sponsor: Cooperative Group

Title:  SWOG S1313: A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma

COH Protocol Number: 12217 ClinicalTrials.gov Number: NCT01638533

Principal Investigator: Vincent Chung, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-72, NCI #9008: A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

COH Protocol Number: 10226 ClinicalTrials.gov Number: NCT01273155

Principal Investigator: Vincent Chung, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-66 NCI#8846- Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction

 
Results per page: 25 50 100 All 1-7 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.